WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis Connects eligible individuals...
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use...
WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the...
WESTLAKE VILLAGE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. Â (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Q1 2026 net product revenue for ZORYVE ® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 Continued strong demand for ZORYVE despite typical...
Barchart Research What to Expect from ARQT Earnings ARQT Generated May 5, 2026 Current Price $23.42 EPS Estimate $$-0.02 Consensus Rating Moderate Buy Average Move 7.56% Arcutis Reports Tomorrow Having...
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well tolerated...